Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.51 |
| ▸ | HPGD | P15428 | 5/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.51 |
| ▸ | GLA | P06280 | 3/20 | 0.51 |
| ▸ | CASP1 | P29466 | 2/20 | 0.51 |
| ▸ | CASP7 | P55210 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.51 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.51 |
| ▸ | ALPG | P10696 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | IGLV6-57 | P01721 | 4/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxamarin SCHEMBL30398534 | 0.99 | KDM4E (0.53) | KDM4ECYP1A2CYP2C19ALDH1A1HPGD | |
| Oxamarin SCHEMBL635068 | 0.99 | KDM4E (0.53) | KDM4ECYP1A2CYP2C19ALDH1A1HPGD | |
| SCHEMBL591362 | 0.81 | KDM4E (0.78) | KDM4ECYP1A2CYP2C19ALDH1A1HPGD | |
| SCHEMBL9229347 | 0.80 | KDM4E (0.60) | KDM4ECYP1A2CYP2C19ALDH1A1HPGD | |
| SCHEMBL9223153 | 0.80 | KDM4E (0.59) | KDM4ECYP1A2CYP2C19ALDH1A1HPGD | |
| SCHEMBL9221587 | 0.80 | KDM4E (0.56) | KDM4ECYP1A2CYP2C19ALDH1A1HPGD | |
| SCHEMBL9367076 | 0.76 | KDM4E (0.54) | KDM4ECYP1A2CYP2C19ALDH1A1HPGD | |
| SCHEMBL8808189 | 0.75 | KDM4E (0.53) | KDM4ECYP1A2CYP2C19ALDH1A1HPGD | |
| SCHEMBL4611432 | 0.73 | KDM4E (0.58) | KDM4ECYP1A2CYP2C19ALDH1A1HPGD | |
| SCHEMBL30819091 | 0.73 | KDM4E (0.66) | KDM4ECYP1A2CYP2C19ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9649093-B2 | Cavity-filling biopsy site markers | SENORX, INC. (US) | 2017-05-16 | — | — | US | claimed |
| US-20160120510-A1 | CAVITY-FILLING BIOPSY SITE MARKERS | SENORX, INC. | 2016-05-05 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20120121724-A1 | FILM COMPRISING THERAPEUTIC AGENTS | MAIBACH TODD (US) | 2012-05-17 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20070059346-A1 | Film comprising therapeutic agents | ACADERM, INC. | 2007-03-15 | — | — | US | claimed |
| CN-1829490-A | Films comprising therapeutic agents | TODD MAIBACH (US) | 2006-09-06 | — | — | CN | claimed |
| EP-1648362-A2 | FILM COMPRISING THERAPEUTIC AGENTS | Maibach, Todd (US) | 2006-04-26 | — | — | EP | claimed |
| US-20050234336-A1 | Apparatus and method for marking tissue | GENERAL ELECTRIC CAPITAL CORPORATION, AS AGENT | 2005-10-20 | — | — | US | claimed |
| US-6862470-B2 | Cavity-filling biopsy site markers | SENORX, INC. (US) | 2005-03-01 | — | — | US | claimed |
| WO-2005004989-A2 | FILM COMPRISING THERAPEUTIC AGENTS | MAIBACH TODD (US) | 2005-01-20 | — | — | WO | claimed |
| EP-1494721-A2 | CAVITY FILLING BIOPSY SITE MARKER | Senorx, Inc. (US) | 2005-01-12 | — | — | EP | claimed |
| WO-2003089012-A2 | CAVITY FILLING BIOPSY SITE MARKER | SENORX, INC. (US) | 2003-10-30 | — | — | WO | claimed |
| US-20020188196-A1 | Cavity-filling biopsy site markers | SENORX, INC. | 2002-12-12 | — | — | US | claimed |
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2024-03-07 | — | — | US | disclosed |
| WO-1999004828-A2 | USE OF HYALURONIC ACID DERIVATIVES IN THE PREPARATION OF BIOMATERIALS | FIDIA ADVANCED BIOPOLYMERS, S.R.L. (IT) | 1999-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | KDM4E 2452/4885CYP1A2 1810/4885CYP2C19 1403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.